Literature DB >> 11883025

[Role of misoprostol in the delivery outcome].

M Benchimol1, J Gondry, J E Mention, O Gagneur, J C Boulanger.   

Abstract

OBJECTIVES: Delivery-induced hemorrhage is defined as a blood loss greater than 500 ml within the first 24 hours after delivery. Loss of more than 1000 ml is a sign of gravity. For certain authors, 40% of these hemorrhages could be avoided with systematic preventive measures using uterotonic agents to control the third phase of labor. The aim of our work was to assess the preventive efficacy of active management measures during the third phase of labor and to determine which agents are most effective. PATIENTS AND METHODS: We compared two protocols for controlled deliver: a conventional method using ocytocin (2.5 IU i.v. bolus), and a more recent method using a prostaglandin E1 analog: misoprostol (Cytotec, 3 tablets per os). We compared the two methods with a control group where no preventive measures were used, the standard procedure in our maternity unit.
RESULTS: Six hundred two women participated in the study. They were divided into 3 homogeneous groups (ocytocin group misoprostol group, control group). There was a 46% reduction in delivery-induced hemorrhage in the ocytocin group but only a minimal preventive effect against severe hemorrhage. Misoprostol did not demonstrate any efficacy in our study. DISCUSSION: It would appear appropriate to take preventive measures against delivery-induced hemorrhage for all deliveries. A bolus intravenous injection of ocytocin immediately after delivery should bed used. The dose should be greater than that used in this study in order to prevent the development of severe hemorrhage. The most satisfactory results can be obtained with 5 IU (1 ampoule of Syntocinon). It is important to obtain a precise quantification of excessive blood loss in order to institute appropriate care rapidly. Misoprostol should be assessed with other prospective studies because of its easy administration, its low cost and easy storage, important advantages in countries with limited resources.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11883025

Source DB:  PubMed          Journal:  J Gynecol Obstet Biol Reprod (Paris)        ISSN: 0150-9918


  6 in total

Review 1.  Prostaglandins for preventing postpartum haemorrhage.

Authors:  Özge Tunçalp; G Justus Hofmeyr; A Metin Gülmezoglu
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

Review 2.  What measured blood loss tells us about postpartum bleeding: a systematic review.

Authors:  N L Sloan; J Durocher; T Aldrich; J Blum; B Winikoff
Journal:  BJOG       Date:  2010-04-20       Impact factor: 6.531

Review 3.  Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects.

Authors:  G Justus Hofmeyr; A Metin Gülmezoglu; Natalia Novikova; Verena Linder; Sandra Ferreira; Gilda Piaggio
Journal:  Bull World Health Organ       Date:  2009-09       Impact factor: 9.408

4.  Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.

Authors:  Ioannis D Gallos; Argyro Papadopoulou; Rebecca Man; Nikolaos Athanasopoulos; Aurelio Tobias; Malcolm J Price; Myfanwy J Williams; Virginia Diaz; Julia Pasquale; Monica Chamillard; Mariana Widmer; Özge Tunçalp; G Justus Hofmeyr; Fernando Althabe; Ahmet Metin Gülmezoglu; Joshua P Vogel; Olufemi T Oladapo; Arri Coomarasamy
Journal:  Cochrane Database Syst Rev       Date:  2018-12-19

Review 5.  Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.

Authors:  Ioannis D Gallos; Helen M Williams; Malcolm J Price; Abi Merriel; Harold Gee; David Lissauer; Vidhya Moorthy; Aurelio Tobias; Jonathan J Deeks; Mariana Widmer; Özge Tunçalp; Ahmet Metin Gülmezoglu; G Justus Hofmeyr; Arri Coomarasamy
Journal:  Cochrane Database Syst Rev       Date:  2018-04-25

Review 6.  Prevention of postpartum haemorrhage: cost consequences analysis of misoprostol in low-resource settings.

Authors:  Danielle L Lang; Fei-Li Zhao; Jane Robertson
Journal:  BMC Pregnancy Childbirth       Date:  2015-11-23       Impact factor: 3.007

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.